Promising epilepsy drug trial halted early – what we know
NCT ID NCT04873869
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested an experimental drug called NBI-921352 in people aged 2 to 21 with a rare, severe form of epilepsy caused by a change in the SCN8A gene. The goal was to see if adding this drug to their current seizure medicines could reduce how often they had seizures. The trial was stopped early, so results are limited, but it aimed to help control seizures rather than cure the condition.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCN8A DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Children's National Hospital
Washington D.C., District of Columbia, 20010, United States
-
Cook Children's Medical Center
Fort Worth, Texas, 76104, United States
-
UCSF Medical Center
San Francisco, California, 94158, United States
-
University of Rochester
Rochester, New York, 14642, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.